Table 3. 4-year survival according to baseline FibroTest, viral load ALT values and treatment.
| Baseline FibroTest Value | n | Death or HBV complications | Survival without HBV complications | HBVRelated Death | Survival without HBV death | Death | Overall Survival | Overall Survival in paired controls |
| 0.00–0.31 | ||||||||
| No or minimal fibrosis | 637 | 4 | 98.9 (97.7–100) | 1 | 99.4 (98.4–100) | 1 | 99.4 (98.4–100) | 99.5 (99.5–99.6) |
| Not treated | 350 | 0 | 100 | 0 | 100 | 0 | 100 | 99.6 (99.5–99.6) |
| Treated | 287 | 4 | 98.0 (96.1–99.9) | 1 | 99.2 (97.5–100) | 1 | 99.2 (97.5–100) | 99.5 (99.4–99.6) |
| 0.32–0.58 | ||||||||
| Moderate fibrosis | 229 | 6 | 94.1 (88.8–99.5) | 1 | 99.4 (98.3–100) | 3 | 98.2 (96.2–100) | 98.5 (98.0–98.9) |
| Not treated | 54 | 1 | 95.2 (86.1–100) | 0 | 100 | 1 | 95.2 (86.1–100) | 98.2 (97.0–99.3) |
| Treated | 175 | 5 | 93.9 (87.9–99.9) | 1 | 99.3 (98.0–100) | 2 | 98.7 (96.9–100) | 98.6 (98.1–99.0) |
| 0.59–1.00 | ||||||||
| Severe fibrosis§ | 208 | 40 | 77.6 (71.3–83.9)* | 25 | 84.2 (77.9–90.5) | 32 | 80.5 (73.8–87.1)§§ | 97.3 (96.7–97.9) |
| Not treated | 24 | 7 | 70.0 (51.4–88.6) | 6 | 74.1 (56.2–92.0)$ | 7 | 70.0 (51.4–88.6)£ | 97.1 (94.6–99.5) |
| Treated | 184 | 33 | 78.7 (71.9–85.4) | 19 | 87.5 (81.8–93.1) | 25 | 81.8 (74.8–88.9) | 97.3 (96.7–97.9) |
| Viral load *** | ||||||||
| Low <2000 IU/ml | 683 | 24 | 94.7 (92.3–97.0) | 12 | 97.5 (96.0–99.0) | 18 | 96.2 (94.4–98.1) | 98.8 (98.6–99.1) |
| Not treated | 332 | 6 | 97.4 (95.2–99.5) | 4 | 98.5 (97.0–99.9) | 6 | 97.4 (95.2–99.5) | 99.1 (98.9–99.4) |
| Treated | 351 | 18 | 93.2 (89.9–96.5) | 8 | 97.0 (94.9–99.2) | 12 | 95.6 (93.1–98.2) | 98.5 (98.3–98.8) |
| Intermediate 2000–20,000 IU/ml | 169 | 2 | 98.8 (97.1–100) | 0 | 100 | 1 | 99.4 (98.1–100) | 99.0 (98.6–99.5) |
| Not treated | 61 | 0 | 100 | 0 | 100 | 0 | 100 | 99.6 (99.5–99.7) |
| Treated | 108 | 2 | 98.1 (95.6–100) | 0 | 100 | 1 | 99.1 (97.2–100) | 98.7 (97.9–99.5) |
| High >20,000**** | 222 | 24 | 85.4 (79.4–91.4) | 15 | 89.2 (82.9–95.5) | 17 | 88.2 (81.8–94.5) | 98.9 (98.5–99.2) |
| Not treated | 35 | 2 | 92.5 (82.3–100) | 2 | 92.5 (82.3–100) | 2 | 92.5 (82.3–100) | 99.6 (99.4–99.8) |
| Treated | 187 | 22 | 84.5 (78.0–91.1) | 13 | 88.8 (81.9–95.8) | 15 | 87.7 (80.6–94.7) | 98.7 (98.3–99.1) |
| ALT | ||||||||
| Very Low <25 IU/L | 317 | 5 | 97.9 (96.0–99.8) | 3 | 98.9 (97.6–100) | 5 | 97.9 (95.9–99.8) | 98.9 (98.7–99.2) |
| Not treated | 176 | 1 | 99.4 (98.3–100) | 1 | 99.4 (98.3–100) | 1 | 99.4 (98.3–100) | 99.3 (98.9–99.6) |
| Treated | 141 | 4 | 96.6 (93.3–99.9) | 2 | 98.4 (96.3–100) | 4 | 96.6 (93.3–99.9) | 98.5 (97.9–98.9) |
| Low 25–49 IU/L | 455 | 16 | 94.0 (90.5–97.5) | 3 | 99.2 (98.2–100) | 8 | 97.7 (96.1–99.3) | 98.9 (98.7–99.2) |
| Not treated | 205 | 3 | 97.4 (94.4–100) | 1 | 99.3 (97.9–100) | 3 | 97.4 (94.4–100) | 99.2 (98.9–99.5) |
| Treated | 250 | 13 | 92.4 (87.6–97.1) | 2 | 99.1 (97.9–100) | 5 | 97.8 (95.9–99.7) | 98.7 (98.3–99.1) |
| Elevated > = 50 IU/L | 302 | 29 | 87.9 (83.6–92.2) | 21 | 89.7 (85.0–94.4) | 23 | 89.0 (84.2–93.8)*$ | 98.7 (98.4–99.0) |
| Not treated | 47 | 4 | 88.9 (78.5–99.2) | 4 | 88.9 (78.5–99.2) | 4 | 88.9 (78.5–99.2) | 99.0 (98.2–99.9) |
| Treated | 255 | 25 | 87.8 (83.2–92.5) | 17 | 89.9 (84.8–95.1) | 19 | 89.1 (83.9–94.3) | 98.6 (98.3–98.9) |
| All | 1074 | 50 | 93.4 (91.4–95.4) | 27 | 96.1 (94.4–97.8) | 36 | 95.0 (93.2–96.8)* | 98.9 (98.7–99.0) |
Survival of the severe fibrosis group was significantly lower than the two other groups (P<0.001).
Overall survival of the severe fibrosis group, treated or not, was significantly lower than that of paired controls (p<0.05).
Overall survival of the 1074 HBV patients, was significantly lower than that of paired controls (p<0.05).
P = 0.03 vs treated.
P = 0.047 vs treated.
Survivals of the treated patients were similar to those of the non –treated in different groups of viral load (p>0.05).
Overall survival of the group with high viral load was lower than that of paired controls (p<0.05).
Overall survival of the group with elevated ALT was lower than that of paired controls (p<0.05).
We used the manufacturers' definitions of normal FT (< = 0.27), normal AT (< = 0.29) and 3 classes for viral load in IU/ml.